Pharmacovigilance Market Size and Share 2027

Market Size – USD 4,820.5 Million in 2019, Market Growth - CAGR of 12.5%, Market Trends –Rise in the development and consumption rate of drugs

The detailed market intelligence report on the Pharmacovigilance market applies the best of both primary and secondary research to weighs upon the competitive landscape and the prominent market players expected to dominate the Pharmacovigilance market for the forecast period, 2020 - 2027. The study not only scans through the company profile of the major vendors but also analyses their winning strategies to give business owners, stakeholders and field marketing personnel a competitive edge over others operating in the same space. A detailed evaluation of the major events such as acquisition and mergers, collaborations, product launches, new entrants, and technology advancements offer a complete overview of what the future of the Pharmacovigilance market will be like in the years to come.

The report provides an in-depth analysis of the impact of the COVID-19 pandemic on the industry. The pandemic has brought a dynamic change in the economic scenario of the world. The report assesses the current market scenario and emerging opportunities and trends due to the COVID-19 pandemic. The market is poised to regain momentum over the next few years due to rapid advancements in the industry. The study also provides a detailed analysis of the present and future impact of COVID-19 on the market.

To know more about the report, visit @ https://www.emergenresearch.com/industry-report/pharmacovigilance-market

Scope of the report

Based on the in-depth analysis the research also brings to light major facts pertaining to the vital aspects such as market share, size, and growth rate. Deep dive into other aspects including the investment feasibility, demand and supply, import and export status, supply chain management and growth prospects narrates a lot about what the business environment will be like for the forecast period,2020 - 2027. All the vital statistics in the report are explained with the help of resources such as tables, charts, and info graphics.

Key market players included in the study are:

ArisGlobal, Accenture, Cognizant, Capgemini, IBM Corporation, IQVIA, BoClinica Inc.,

Laboratory Corporation of America Holdings, Linical Accelovance, and ITClinical, among others.

The report analyzes the strategic alliances observed in the market for new products, partnerships, and collaborations between key players. The report investigates key aspects such as financial standing, research and development, product offerings, current deals, investments, and strategic alliances such as mergers and acquisitions, joint ventures, product launches, brand promotions, and corporate deals, among others.

Type Outlook (Revenue, USD Million; 2017-2027)

•          Spontaneous Reporting
•          Intensified Adverse Drug Reaction (ADR) Reporting
•          Targeted Spontaneous Reporting
•          Cohort Event Monitoring
•          Electronic Health Record (HER) Mining

Service Provider Outlook (Revenue, USD Million; 2017-2027)

•          In-House
•          Contract Outsourcing

Clinical Trial Phase Outlook (Revenue, USD Million; 2017-2027)

•          Pre-Clinical
•          Phase I
•          Phase II
•          Phase III
•          Phase IV

End-Users Outlook (Revenue, USD Million; 2017-2027)

•          Hospitals
•          Research Organizations
•          Others

The study further explores and provides an in-depth analysis of current market dynamics and recent trends, focusing on various key factors and potential growth opportunities and risks. The report focuses on leading regions and their major countries to anticipate market growth in the forecast years. The major geographical regions included in the study are North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. 

Key Highlights from The Report

•          In December 2019, UCB and Accenture made an announcement about signing of a partnership agreement to build a safety solution on INTIENT™ pharmacovigilance, by Accenture, to accelerate patient safety case reports’ processing. The agreement is intended to help UCB in discovering the influence of existing treatments on patient’s safety and therefore managing the novel drugs’ risk in a better way.
•          Spontaneous reporting is a crucial type in pharmacovigilance by providing information from real clinical settings in the course of a drug’s life. Physicians and many other healthcare specialists contribute immensely to improving public health by supposed adverse drug reactions’ reporting.

The complete regional analysis covers:

•          North America (U.S., Canada, Mexico)
•          Europe (U.K., Italy, Germany, France, Rest of EU)
•          Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
•          Latin America (Chile, Brazil, Argentina, Rest of Latin America)
•          Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Thank you for reading our report. For customization inquiries or further information, please connect with us, and we will ensure you get the report that meets your requirements.  

About This Author

peter Joined: November 5th, 2020